Adenovirus 5 vector genetically re-targeted by an affibody molecule with specificity for tumor antigen HER2/neu
2007 (English)In: Cancer Gene Therapy, ISSN 0929-1903, E-ISSN 1476-5500, Vol. 14, no 5, 468-479 p.Article in journal (Refereed) Published
In order to use adenovirus (Ad) type 5 (Ad5) for cancer gene therapy, Ad needs to be de-targeted from its native receptors and re-targeted to a tumor antigen. A limiting factor for this has been to find a ligand that (i) binds a relevant target, (ii) is able to fold correctly in the reducing environment of the cytoplasm and (iii) when incorporated at an optimal position on the virion results in a virus with a low physical particle to plaque-forming units ratio to diminish the viral load to be administered to a future patient. Here, we present a solution to these problems by producing a genetically re-targeted Ad with a tandem repeat of the HER2/neu reactive Affibody molecule (ZH) in the HI-loop of a Coxsackie B virus and Ad receptor (CAR) binding ablated fiber genetically modified to contain sequences for flexible linkers between the ZH and the knob sequences. ZH is an Affibody molecule specific for the extracellular domain of human epidermal growth factor receptor 2 (HER2/neu) that is overexpressed in inter alia breast and ovarian carcinomas. The virus presented here exhibits near wild-type growth characteristics, infects cells via HER2/neu instead of CAR and represents an important step toward the development of genetically re-targeted adenoviruses with clinical relevance.
Place, publisher, year, edition, pages
2007. Vol. 14, no 5, 468-479 p.
adenovirus, Affibody molecules, re-targeting, HER2/neu, fiber, HI-loop, staphylococcal protein-a, fiber protein, gene-transfer, intracellular trafficking, receptor antibodies, cellular receptor, knobless fibers, binding site, cancer, domain
IdentifiersURN: urn:nbn:se:kth:diva-16550DOI: 10.1038/sj.cgt.7701027ISI: 000245650900004ScopusID: 2-s2.0-34247168525OAI: oai:DiVA.org:kth-16550DiVA: diva2:334592
QC 201005252010-08-052010-08-05Bibliographically approved